Kornimate/medical-research-clean huggingface dataset:
the relationship between academic burnout and psychological resilience

Conditions: Burnout; Resilience; Coping

Summary: a cross sectional study of prevalence and correlates of burnout and resilience among indergraduate medical students

a questionnaire based cross sectional study of the relationship between academic burnout and psychological resilience among undergraduates medical students, faculty of medicine, mansoura university

Eligibility criteria:
inclusion criteria: - undergarduate medical students at mansoura faculty of medicine exclusion criteria: * graduate students and interns

Keywords: burnout resilience coping
the safety and immunogenicity of acellular pertussis vaccine in bone marrow transplant recipients

Conditions: Pertussis

Summary: the purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.


Eligibility criteria:
inclusion criteria: * aged 18-64 * bmt at the qeii health sciences centre * bmt within last 12 months * able to read and write english language * able to give consent exclusion criteria: * active infection * active gvhd * recent ivig * allergy to components of vaccine * diphtheria or tetanus vaccination within 18 months

Keywords: pertussis bone marrow transplant
randomized trial of dietary intervention therapy in obese hypertensives (ditoh)

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension; Obesity

Summary: to determine the effects on blood pressure of dietary intervention, restricting caloric intake to 600 calories per day for 16 weeks compared to a control diet of 1200 calories per day in obese hypertensives. secondary aims included a study of psychological characteristics at baseline and during the weight loss and maintenance phases of the study.

background: hypertension is a highly prevalent disorder contributing to a large proportion of cardiovascular morbidity and mortality in the united states. although drug therapy of elevated blood pressure can reduce the risks of cardiovascular morbidity and mortality, such therapy constitutes significant expense for individuals over long periods of time as well as large national expenditures. in addition, the side effects of drug therapy may be significant. ditoh would provide much needed information concerning the effects of various means of weight reduction on blood pressure as possible definitive therapy for hypertension or as an approach which could be combined with reduced drug dosages. design narrative: randomized. after three weeks on a control diet, subjects were randomized to the protein sparing modified fast diet which provided 600 calories per day (1.5 grams per kilogram of ideal body weight of high quality protein plus 19 grams of fat) or to a 1200 calorie per day balanced deficit diet. after 16 weeks in the weight-loss phase, subjects entered the maintenance program for 20 weeks. both diets were supplemented with vitamins, minerals, and fluids. the protein sparing modified fast diet was supplemented with 5 grams of salt given as bouillon to equal the salt intake of the balanced deficit diet. patients were followed for 24 months after the end of the weight loss phase. the primary endpoint was change in diastolic blood pressure. individuals who continued to have diastolic pressures above 104 mm hg following the initial 16 week treatment period were treated with antihypertensive drugs. the study completion date listed in this record was obtained from the query/view/report (qvr) system.

Eligibility criteria:
men and women, ages 25 to 55. subjects were obese, weighing between 130 and 210 percent of ideal body weight. subjects had diastolic blood pressures between 90 and 105 mm hg and were not on antihypertensive medications.
pre-operative stereotactic radiosurgery followed by resection for brain metastases

Conditions: Malignant Neoplasm Brain

Summary: the primary goal of this research study is to determine the efficacy of giving pre-operative radiosurgery to patients pending resection of a brain metastasis.

patients who have a brain metastasis surgically resected have very high local rates of disease relapse, and so the standard of care is to give either whole brain irradiation or stereotactic radiosurgery to the resection cavity in order to prevent disease recurrence. stereotactic radiosurgery generally offers a more favorable side effect profile than whole brain irradiation, but targeting a surgical resection bed can be a challenge, as post surgical changes make it more difficult to distinguish residual tumor from scar, and much of the dose ends up being focused on the center of the resection cavity, where there are no substantial tumor cells.

Eligibility criteria:
inclusion criteria: * life expectancy of at least 12 weeks * karnofsky performance status of at least 50 * no contraindications to mri scanning with intravenous contrast. * mri scan consistent with brain metastasis as per radiology report. * target lesion must measure at least 15 mm in at least one dimension, and no more than 4 cm in any dimension. * patients must have an extra-cranial primary tumor diagnosis. * patients will have no more than 4 distinct lesions within the brain. at least 1 lesion has been recommended for surgical removal based on size, symptomology, or regional mass effect on the brain. * additional lesions will each be treated with stereotactic radiosurgery. * patients with a documented symptomatic lesion size smaller than 3cm requiring clinical surgical resection * must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks and discomforts exclusion criteria: * primary tumor histology of lymphoma, leukemia, multiple myeloma or germ cell tumor. moribund status or status epilepticus. * supratentorial mass effect with greater than 5 mm of midline shift or hydrocephalus. infratentorial mass effect with fourth ventricle effacement or hydrocephalus. * more than four additional diagnosed brain metastases. * contraindication to general anesthesia. * adjacent tumor location to optic apparatus or brainstem, precluding achievement of meaningful dose with srs. * primary brain tumor. * contraindication to mri scans or intravenous contrast. * pregnant and breast-feeding females.
diagnosis of cardiac amyloidosis with 99mtc-pyp; comparison between planar imaging, spect/ct and cardiac-dedicated czt camera

Conditions: Cardiac Amyloidosis

Summary: 1. patients will undergo clinical and laboratory assessment, as well as imaging tests, at the discretion of the attending cardiologist and will be referred at their discretion to perform cardiac mapping using 99mtc-pyp. 2. on the day of the examination, the examiner will be admitted to the office of nuclear medicine and will be admitted to administrative. before conducting the test, the subject will undergo a brief interview by a physician, receive an explanation of the study and, if agreed, sign an agreement to perform a further examination on the czt camera. 3. the patient will, as is customary, be installed on vanflon 22 g periphery, through which a 15 millikiric (mci) of


Eligibility criteria:
inclusion criteria: a. patients undergoing "cardiac amyloidosis clinic" at tel aviv medical center and there is a clinical suspicion of having cardiac amyloidosis. b. patients who performed will be referred for mapping using 99mtc-pyp and sign a consent form to take another photograph, under the cardiac-dedicated czt camera exclusion criteria: 1.none
a single dose study of pf-05161704 in healthy volunteers

Conditions: Diabetes Mellitus, Type 2

Summary: the primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of pf-05161704 in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy male and/or female (non child-bearing potential) subjects between the ages of 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests). * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * any condition possibly affecting drug absorption (eg, gastrectomy). * history of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor) within 6 months of screening. * history or evidence of habitual use of tobacco or nicotine containing products within 3 months of screening or positive cotinine test at screening or day 0 of period one

Keywords: single ascending dose phase 1 safety and tolerability pk healthy subjects
the effects of music on the anxiety and sleep quality of pregnant women on bed rest for a high-risk pregnancy

Conditions: Pregnancy, High Risk; Anxiety State; Sleep Quality

Summary: the purpose of this study is to identify the effects of music on the anxiety and sleep quality of women with high-risk pregnancy having bed rest in the hospital in turkey. this randomized-controlled study involved 80 control and 80 experimental group with a high-risk pregnant woman .

the literature review indicates a limited number of studies on the effects of music in eliminating the anxiety and sleep problems in women with a high-risk pregnancy having bed rest in the hospital; the existing studies were found to be mainly about anxiety. the purpose of this study is to identify the effects of music on the anxiety and sleep quality of women with a high-risk pregnancy having bed rest in the hospital. this study adopted a pretest-posttest randomized controlled study involved 80 control and 80 experimental group with a high-risk pregnant woman . the women in the experimental group listened to acemaşiran music for 40 minutes in successive three days and two times a day.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the study * knowing turkish and being literate * having been hospitalized for bed rest for at least 5 days. * having a gestational age of 28 to 36 weeks * being hospitalized due to at least one of the diagnoses including hypertensive diseases, diabetes mellitus, preterm labor, placenta previa, cervical insufficiency, or premature rupture of the membrane exclusion criteria: * fetal congenital anomalies * having a hearing impairment

Keywords: anxiety bed rest high-risk pregnancy music sleep quality
efficacy and safety of lumiracoxib

Conditions: Osteoarthritis

Summary: this trial assessed the safety and efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to a single dose of celecoxib 200mg. it also assessed safety and efficacy of 400mg lumiracoxib administered once a day for 7 days compared to placebo and to 200 mg celecoxib twice daily.


Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee * pain intensity at baseline of at least 50mm on a 100mm visual analog scale other protocol-defined inclusion/exclusion criteria may apply

Keywords: lumiracoxib osteoarthritis
live versus inactivated influenza vaccine study in hutterite children

Conditions: Influenza

Summary: there is uncertainty about whether a live attenuated vaccine (laiv) offers additional benefit over inactivated trivalent influenza vaccine (tiv) in providing indirect benefit to those who are unvaccinated through herd immunity. the goal of this randomized clinical trial is to determine whether immunizing children in hutterite colonies with laiv can provide increased community-wide protection over tiv. children aged 3 to 15 years in hutterite colonies from alberta and saskatchewan will be randomized to one of two regimens: tiv or laiv. the primary outcome of this study will be laboratory-confirmed influenza as detected by pcr in all participants (i.e vaccine recipients and nonrecipients). secondary outcomes will include influenza-like illness, hospitalization, pneumonia, death, antibiotic use, absenteeism.

the goal of this study is to test whether immunizing children in hutterite colonies with laiv can significantly reduce laboratory-confirmed influenza in the entire community compared to tiv. we hypothesize that ≥70% uptake of laiv compared to a similar uptake of tiv among healthy children and adolescents will reduce laboratory-confirmed influenza in laiv colonies by 50% compared to tiv colonies. other specific objectives are to determine if laiv reduces influenza in the healthy children and adolescents immunized and if laiv reduces the following relative to tiv in all participants: influenza-like illness, antimicrobial prescriptions, physician-diagnosed otitis media, school or work-related absenteeism, physician visits for respiratory illness, lower respiratory infection, pneumonia, hospitalizations, and death. we will assess reactogenicity in both study groups.

Eligibility criteria:
group a: inclusion criteria: * healthy children and adolescents aged 36 months to 15 years who will be immunized as part of the intervention. exclusion criteria: 1. anaphylactic reaction to a previous dose of laiv or tiv 2. known ige-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock 3. history of asthma 4. medically diagnosed or treated wheezing within 42 days before enrollment 5. guillain-barré syndrome within eight weeks of a previous influenza vaccine 6. anaphylactic reaction to gentamicin 7. anaphylactic reaction to gelatin 8. anaphylactic reaction to neomycin 9. anaphylactic reaction to arginine 10. pregnancy 11. household contact who is severely immunocompromised being cared for in a protective environment (i.e hematopoietic stem cell transplant) 12. use of aspirin or salicylate-containing products within 30 days before enrollment. group b: inclusion criteria * other hutterite community members that are not in group a exclusion criteria: * there are no exclusion criteria for this category of participants
intrauterine saline washing for detection endometrial disease in patients with abnormal uterine bleeding

Conditions: Endometrial Disease

Summary: investigator will examined the diagnostic effect of the endometrial washing by saline. because this technique more less painful and easier compared to endometrial curettage. participants will separate into two groups. in study groups before endometrial curettage 5 cc saline infused to the endometrial cavity then aspirate and put into thin prep to examined. after this procedure routine endometrial curettage will be done. in control group only endometrial curettage will be done. pathologic results of thin prep and curettage will compared.


Eligibility criteria:
inclusion criteria: * abnormal uterine bleeding exclusion criteria: * involuntary, under 35 years old,
pmt for mdro decolonization

Conditions: Multidrug Resistant Bacterial Infection; Enterobacteriaceae Infections; Pseudomonas Aeruginosa; VRE Infection; Methicillin-resistant Staphylococcus Aureus

Summary: this is a randomized, open label, comparative phase ii trial being conducted to determine whether fecal microbiota transplant using penn microbiome therapy (pmt) products helps standard therapy eradicate antibiotic-resistant bacteria.


Eligibility criteria:
inclusion criteria: 1. multidrug-resistant organism (mdro) infection of the bloodstream, respiratory tract, or urinary tract. qualifying mdros include extended-spectrum cephalosporin-resistant enterobacterales (escre) or carbapenem-resistant enterobacterales (cre), pseudomonas aeruginosa non-susceptible to two or more classes of antibiotics (mdr-pa), vancomycin-resistant enterococcus (vre), and methicillin-resistant staphylococcus aureus (mrsa). 2. on appropriate antibiotic treatment per clinical phenotypic susceptibility testing of the qualifying mdro, and with a qualifying antibiotic class. qualifying antibiotic classes include beta-lactam + beta-lactamase inhibitor, carbapenem (with or without betalactamase inhibitor), fluoroquinolone, lipopeptide, glycopeptide, or oxazolidinone. 3. expected duration of inpatient antibiotic treatment for index mdro infection at least 5 days total. 4. at least two calendar days remaining, and no more than 7 calendar days remaining prior to scaim (scheduled completion of inpatient appropriate antibiotics for the index mdro infection). 5. age ≥ 18 years. exclusion criteria: 1. evidence of colon/small bowel perforation at the time of study screening. 2. unable to tolerate enteral and enema nutrition and medication administration (i.e., only able to tolerate intravenous nutrition and medications). 3. goals of care are directed to comfort rather than curative measures. 4. moderate or severe neutropenia within 10 calendar days prior to enrollment. 5. known food allergy that could lead to anaphylaxis. 6. known allergy to fecal microbiota transplant products or their components 7. pregnancy or lactation 1. for subjects of childbearing potential (ages 18 to 55) and who are randomized to receive the intervention, the subject must have a negative pregnancy test within 24 hours prior to product administration 2. female or male subjects (ages 18 to 55) of reproductive potential engaged in active sexual activity that could lead to a pregnancy must agree to use one of the following forms of birth control while receiving study medications and through day 28 following completion of treatment, at minimum: i. male or female condoms ii. diaphragm or cervical cap with spermicide, if available iii. intrauterine device (iud) iv. oral contraceptives or other hormonal contraception 8. known gastrointestinal disease that could affect the safety of fecal microbiota transplant at time of enrollment: 1. inflammatory bowel disease (ibd) 2. short gut syndrome 3. fistulas 4. bowel resection surgery 5. colitis
safety and efficacy of nabota in treatment of essential blepharospasm

Conditions: Blepharospasm

Summary: the purpose of this study is to evaluate the efficacy and safety of nabota in treatment of essential blepharospasm


Eligibility criteria:
inclusion criteria: * male of female of at least 18 years old * grade 2\~4 in scott's scale
advanced harmonic generation microscopy for treatment assessment of cutaneous pigmentary disorder

Conditions: Solar Lentigo; Nevus Zygomaticus

Summary: in this study, the investigators demonstrated that in vivo thg microscopy can differentiate solar lentigos (sl), nevus zygomaticus(nz) and normal skin based on the optical nature of melanin. this thg-based procedure provides a valuable tool for noninvasive determination of third-order nonlinear susceptibility of melanin within the skin. it can also provide real-time histopathology information for treatment follow-up, without performing an invasive skin biopsy.

a nonrandomized, controlled, split-face comparative study was conducted to compare the efficacy and safety between quality-switched ruby laser (qsrl) and 532-nm picosecond nd:yag laser (532-psnyl for sl, 1064-psnyl for nz) in the treatment of solar lentigo clinically and histologically by harmonic generation microscopy (hgm). after baseline photography and in vivo harmonic generation microscopy (hgm) imaging, qsrl and 532-psnyl or 1064-psnyl therapy for solar lentigos and nevus zygomaticus on the left and right side of the face, respectively, were performed for each subject. the subjects underwent follow-up assessment at weeks 3 and 6. statistical analysis: all data gathered went through decoding and were analyzed by blinded evaluators using spss software (version 20.0; ibm, armonk, ny). all tests were two-sided. a p value of \< .05 was considered to be statistically significant.

Eligibility criteria:
1. main inclusion criteria: 1. subjects are aged 20 to 85 years at screening, and can be either sex. 2. subjects are fitzpatrick skin type iii or iv. 3. subjects must have been diagnosed to have solar lentigos or nevus zygomaticus, which are larger than 4 mm in diameter on both sides of the face. 2. main exclusion criteria: 1. subjects have previous treatments on the solar lentigos or nevus zygomaticus. 2. subjects have a history of adverse reaction to laser treatments, including allergy to topical anesthesia application. 3. subjects have a history of chronic inflammatory disorder such as atopic dermatitis on the face. 4. subjects are pregnant or breast feeding. 5. subjects have frequent sun exposure (≥4 hours per day).

Keywords: solar lentigo nevus zygomaticus harmonic generation microscopy in vivo
reflectance confocal microscopy to diagnose bcc

Conditions: Basal Cell Carcinoma

Summary: it is proposed to undertake a study to determine the diagnostic utility of using rcm for the diagnosis of basal cell carcinoma (bcc) in a tertiary referral centre as outlined by the recent nice report (nov 2015). this will allow an assessment of the potential to avoid diagnostic biopsy within the treatment pathway.

study design this is an observational, non-randomised, non-controlled, prospective cohort study to look at the efficacy of in vivo rcm as a diagnostic tool in the diagnosis of bcc. study hypothesis the hypothesis of this study is that the use of rcm is would enable a reduction in the number of diagnostic biopsies taken before definitive treatment of bcc by at least 50%. the secondary hypothesis is that the intra- \& inter-observer agreement for interpreting the rcm images will have kappa scores 0.6 or greater (indicating good agreement). patients will be recruited from the outpatient clinic of skin care network london.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. patient suspected of having a primary basal cell carcinoma that is a candidate for surgical treatment. 3. patient willing and able to give informed consent exclusion criteria: 1. recurrent or other higher-risk bcc 2. patient with basal cell naevus syndrome 3. patient treated with hedgehog inhibitor medication (vismodegib) 4. patient not suitable for diagnostic biopsy 5. location of lesion unsuitable, inaccessible or impractical for scanning with rcm as determined by investigator 6. patient with co-morbidities such as other skin disease

Keywords: confocal rcm imaging skin cancer